Men and women with schizophrenia aged 18-65 yrs
Total PANSS <=70

**Treatment A**
(N=186)

- Screening
- Day 1 injection: 234 mg (Deltoid)
- Day 8 injection: 234 mg (Deltoid)
- Day 36 to Day 344 Study medication dosing
  - Day 1: Predose 24, 72 and 120 hours
  - Predose or same time as prior injection: Days 8, 11, 15, 18, 20, 22, 29, 36, 41, 64, 92, 99, 120, 148, 155, 176, 179, 183, 186, 188, 190, 197, 204, 232, 260, 288, 316, 344, 347, 351, 354, 356, 358, 365, 372
- PK Sampling
- Unable to tolerate 234 mg or unwilling to participate in intensive PK sampling
- Discontinuations (n=86)
  - Patient choice (n=27)
  - Adverse event (n=23)
  - Lack of efficacy (n=15)
  - Lost to follow-up (n=9)
  - Other (n=12)
- Study Completion (n=100)

**Treatment B**
(N=26)

- Screening
- Day 1 injection
- Day 8 injection: 234 mg (Deltoid or Gluteal)
- Day 36 to Day 344 Study medication dosing
  - Day 1: Predose 78, 120, 176, 232, 288, 344
  - Predose or same time as prior injection: Days 8, 64, 120, 176, 232, 288, 344
- PK Sampling
  - Fixed Dose: Days 1, 36, 118, 183, 232, 288, 344
  - Flexible Dose: Days 8, 64, 120, 176, 232, 288, 344
- Unable to tolerate 234 mg or unwilling to participate in intensive PK sampling
- Discontinuations (n=13)
  - Patient choice (n=2)
  - Adverse event (n=5)
  - Lack of efficacy (n=2)
  - Lost to follow-up (n=3)
  - Other (n=1)
- Study Completion (n=13)